AI-generated · cited to primary sources · not investment advice
Marksans Pharma (524404) Feb 2026 Filing Analysis
Does management do what it says?
Management expects the U.S. business to grow at approximately 20% in the upcoming financial year. — target: 20%
“Ahmed: So does that sort of reflect that we should be able to grow at 20% odd in U.S. in the upcoming financial year? Mark Saldanha: Yes, very close to that, yes. Sure.”
See the full cited Management analysis of Marksans Pharma
How durable is the business?
Operating leverage is expanding as the Unit 2 (Teva) facility ramps up, though margins were temporarily impacted by headcount additions at this site. The facility successfully passed a US FDA inspection with zero observations. (1 expanding)
“Accreditations: USFDA, UK MHRA, Australian TGA, EU and Health Canada.”
Profitability is expanding due to operating leverage from the Teva facility and softening raw material prices, leading to a 184 bps gross margin expansion. (1 expanding)
“The gross margin expansion of 184 basis points on a year-on-year basis is attributed to softening of raw material prices, a favourable product mix and also from benefits from foreign exchange movements.”
The UK and EU formulation business grew 9.2% for the full year, with the UK region achieving its highest quarterly revenue of the year in Q4. (5 expanding)
“US & North America Rs. 412.4 cr, 16.9% YoY, 54.7% share.”
The Over-the-Counter (OTC) segment reached a record high, crossing the Rs. 2,000 crore mark for the full year, driven by pipeline expansion and strong execution. (5 expanding across 2 engines)
“Revenue by Segment: OTC 74.1%, Rx 25.9%. Our OTC segment grew at a CAGR of 21% (from FY17 to FY25)”
See the full cited Business Model analysis of Marksans Pharma
Where does growth come from?
Revenue from the acquired Teva facility is scaling up; while it contributed Rs. 325 Cr in FY25, it is currently trending at a run-rate of Rs. 400-500 Cr for FY26, moving toward the Rs. 1,000 Cr peak capacity target. (5 accelerating across 5 signals, 2 leading indicators)
“No, I mentioned in the next 2 to 3 years is INR 4,000 crores odd, not INR 5,000 crores... Next 2 to 3 years, yes. FY28 or FY29.”
The U.S. order book is showing strong forward momentum, with management projecting an increase to $300 million within two years, despite current geopolitical uncertainties. (1 accelerating, 2 steady across 3 signals)
“Yes. Our order book still stands at a very strong $220 million plus. We are still working towards our objective of going to the next milestone.”
The US market is accelerating, showing 35% YoY growth in FY25, driven by a strong OTC pipeline and the goal to double US store brand OTC revenue. (3 accelerating, 2 steady across 5 signals, 3 leading indicators)
“Aim to double US store brand OTC revenue”
Marksans is aggressively expanding its product pipeline with over 100 products currently in development to sustain growth momentum. (+1 more signal)
“Continued focus on R&D investments leading to a robust pipeline of new developed & pipeline products... Products in Pipeline 100+”
US revenue shows strong acceleration in the most recent quarter (16.9% YoY) compared to the 9M average, driven by seasonal demand and new product launches. (1 accelerating across 1 signal)
“The performance is despite a high single-digit price erosion in the Rx product segments.”
See the full cited Future Growth analysis of Marksans Pharma
What could break the thesis?
The Teva facility integration is progressing but slower than expected; Q4 volumes were 200 million units against a target of 400-500 million. Revenue from the plant was Rs. 325 crores for FY25, below the eventual Rs. 1,000 crore target. (5 intensifying)
“Working capital cycle ~151 days for Q3FY26”
The risk has intensified as the UK market saw 'abnormal' price erosion in the Rx (prescription) segment, which management attributes to a 'cascading effect' of US tariff uncertainties forcing competitors to offload products in the UK. Revenue in the UK/EU segment dropped to INR 203.8 crores from INR 258.2 crores previously. (1 intensifying, 4 easing, 1 high-severity)
“US & North America ₹ 412.4 cr (54.7%) | UK & Europe ₹ 258.2 cr (34.2%)”
Management reports that price erosion for Rx products has stabilized, which is a positive shift from previous quarters where it was a primary concern for margin pressure. (4 easing, 1 stable)
“Price erosion in Rx products remained in the high single-digit range.”
Integration and expansion costs (Goa facility) and higher R&D (up 66% YoY) continue to impact EBITDA margins, which fell to 17.8% in Q4. (1 stable, 1 intensifying)
“Almost 3% of your total spends are towards R&D. However, we've not seen a material escalation in growth.”
See the full cited Risk analysis of Marksans Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.